Last reviewed · How we verify
prednison
At a glance
| Generic name | prednison |
|---|---|
| Sponsor | Wen Zhang |
| Target | Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acquired thrombocytopenia
- Acute lymphoid leukemia
- Adrenal cortical hypofunction
- Adrenogenital disorder
- Allergic rhinitis
- Angioedema
- Ankylosing spondylitis
- Articular gout
- Asthma
- Atopic dermatitis
- Autoimmune disease
- Autoimmune hemolytic anemia
- Berylliosis
- Chronic lymphoid leukemia, disease
- Congenital hypoplastic anemia
- Contact dermatitis
- Crohn's disease
- Dermatitis herpetiformis
- Diffuse Proliferative Lupus Nephritis
- Diffuse non-Hodgkin's lymphoma, large cell
Common side effects
- Hypertension or aggravation of hypertension
- Edema
- Increased appetite and weight gain
- Nausea
- Fluid retention
- Acne
- Insomnia
- Mood changes
- Increased sweating
- Headache
- Dizziness
- Nervousness
Serious adverse events
- Anaphylaxis
- Cardiac arrest
- Circulatory collapse
- Myocardial rupture following recent myocardial infarction
- Peptic ulcer with possible perforation and hemorrhage
- Perforation of the small and large intestine
- Pancreatitis
- Adrenal insufficiency
- Aseptic necrosis of femoral and humeral heads
- Tendon rupture
Key clinical trials
- Reducing Dexamethasone Around Docetaxel Infusion (PHASE1)
- Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) (PHASE2)
- Short-term Glucocorticoid Combined with MMF for IgG4-RD (NA)
- Bendamustine Plus Rituximab Versus CHOP Plus Rituximab (PHASE3)
- Oral Corticosteroids for Post-infectious Cough in Adults (PHASE3)
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma (PHASE3)
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma (PHASE2)
- Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prednison CI brief — competitive landscape report
- prednison updates RSS · CI watch RSS
- Wen Zhang portfolio CI